FAST NEWS: Simcere Pharma New Co-CEO Sends Investors Scurrying

The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) announced late Wednesday that executive director Tang Renhong has been appointed as Co-CEO and will assist Chairman and CEO Ren Jinsheng in leading the company’s R&D business. Looking up: Tang has a PhD in molecular cell biology from Nanyang Technological University in Singapore and nearly 12 years of experience working in drug company R&D and management, including tenures at Shanghai Shengdi Pharmaceutical and AstraZeneca Investment (China). His expertise and experience may help to improve the company’s new drug development efforts. Take Note: The…

Read More »

I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat

Cancer drug maker has been in a wide range of market-moving headlines lately, though its stock still trades near an all-time low Key Takeaways: I-Mab was placed on a list of stocks at danger of being delisted from the U.S., just a week after it announced two major new executive appointments Company is reportedly exploring a potential sale to a western pharma giant, or a possible merger with a smaller peer By Shirley Lau There’s no shortage of market-moving news these days about up-and-coming cancer drug maker I-Mab (IMAB.US), whose…

Read More »

FAST NEWS: InnoCare Pharma Sees Losses Shrinking, But Stock Still Slumps

The latest: Drug maker InnoCare Pharma Ltd. (9969.HK) announced Wednesday evening that it expects to report a net loss of up to 100 million yuan ($15.7 million) for all 2021, a significant 78.4% reduction from the 464 million yuan net loss recorded in 2020. Looking up: For biotech stocks, where R&D expenses account for the majority of costs, a decrease in losses is always good news, showing the company is edging closer to profitability. The reduced loss is mainly due to the company’s receipt last year of an up-front licensing…

Read More »

FAST NEWS: Legend Biotech Halts Trials for LB1901 CAR-T Therapy Drug

The latest: Legend Biotech Corp. (LEGN.US) announced that the Phase 1 clinical trial for its LB1901 drug has been put on hold. LB1901 is the company’s autologous chimeric antigen receptor T-cell (CAR-T) therapy drug for treatment of adults with relapsed or refractory T-cell lymphoma (TCL). Looking Up: LB1901 was never intended as a mass market drug. In the prospectus for its 2020 IPO, Legend said: “Some of our clinical trials are designed to enroll patients with characteristics that are found in a very small population. For example, our planned Phase…

Read More »

I-Mab Founder Retakes Reins in Latest Shakeup Ahead of Commercialization Phase

Drug maker announces latest senior appointments as investors anticipate regulatory approval for some of its products as early as 2023 Key takeaways Four-year company veteran and CEO Joan Shen to depart I-Mab as chairman and founder Zang Jingwu gets set to resume the role Analysts upbeat as company earmarks 2023 for regulatory approval of key drugs and launch of production facility By Richard Barbarossa In a twist on an old adage, it appears to be a case of “out with the old and in with the not-so-new,” at drug developer…

Read More »

Kintor Pharma Gets Mega-Booster from Experimental Covid-19 Drug

Company posted major milestone last week with the first emergency use authorization for its drug Proxalutamide to treat the coronavirus in Paraguay Key points:  Kintor Pharma’s Proxalutamide could become a blockbuster drug if it receives emergency use approval in the U.S. as a treatment for Covid-19 The company’s stock has jumped sevenfold this year, outpacing even the most bullish analyst targets By Alice Leung It’s relatively rare to see a stock trade higher than analysts’ targets, since such people tend to be quite bullish on the companies they follow. But…

Read More »

Drug Maker I-Mab Wins Plaudits as Analysts Urge Caution on Soaring Stock

Cancer specialist’s shares have nearly doubled in the last six months after it posted its first-ever profit and named two well-connected board members Key points: I-Mab’s shares have nearly doubled over the past six months on major licensing deal, fundraising and pending drug approvals Appointment of two new well-connected board members could expedite first approvals of company’s drugs in China By Richard Barbarossa Cancer drug developer I-Mab (IMAB.US) has been on a roll this year. The company’s shares have nearly doubled in the past six months after it recorded its…

Read More »

Pharmaron, I-Mab and Burning Rock Get Investor Validation From MSCI

Three up-and-coming Chinese pharma companies are among those included in latest adjustment for the index compiler’s China All Shares Index Key takeaways: MSCI’s addition of Pharmaron, I-Mab and Burning Rock to its China All Shares Index highlights their strong growth potential Inclusion typically represents validation for a company’s products and outlook By Richard Barbarossa Drug and healthcare R&D firms are well-represented in the latest round of additions to the MSCI China All Shares Index, highlighting the sector’s growth potential and strong fundamentals. Some new ascendants to the list are even…

Read More »

Undervalued Zai Lab on Licensing Binge to Boost Cancer Treatment Portfolio

With $860 million in new cash from a recent share sale, company seeks to accelerate approval and rollout of new cutting-edge treatments from abroad Key takeaways: Zai Lab’s revenue should continue to surge on new product approvals and inclusion of a core product on the National Reimbursement Drug List Company’s losses could continue to balloon as it pursues expensive new licensing deals at the cost of near-term profits By Richard Barbarossa Cancer and autoimmune drug specialist Zai Lab Ltd.(Nasdaq: ZLAB; 9688.HK) is poised to accelerate approval of new medicines and…

Read More »

CStone Finds Tonic in Steady Stream of Drug Approvals, Licensing Deals

Cancer drug specialist reported its first significant revenue in 2020, following a string of milestones capped by a $200 million investment from Pfizer Key takeaways: Strong upfront licensing fees helped CStone post its first-ever significant revenues and narrowing losses in 2020 The company is eying new approvals for more uses of its cancer drugs as big-name global pharma companies pump it up with cash By Richard Barbarossa CStone Pharmaceuticals Co. Ltd (2616.HK), a Chinese maker of immuno-oncology therapies and precision medicines, is moving closer to profitability after its losses narrowed…

Read More »